ADA: TZD Debate Rages, but What Does It Mean?
http://www.medpagetoday.com/MeetingCo...
ORLANDO -- Safety issues -- especially cardiovascular risks -- continue to dog rosiglitazone (Avandia) and echo in faint whispers that touch its classmate, pioglitazone (Actos). As a result, the question that emerged here at the American Diabetes Association meeting was all-encompassing -- should the thiazolidinedione class continue to be used at all?
The controversy, which has been simmering for three years, heated up in anticipation of next month's FDA advisory committee meeting to consider whether to pull troubled rosiglitazone from the market.
Medpage Today: http://medpagetoday.com
Online CME - Continuing medical education: http://www.medpagetoday.com/cme/
Latest medical news: http://www.medpagetoday.com/latest/
The MedPage Today app:
iOS: https://goo.gl/JKrkHq
Android: https://play.google.com/store/apps/de...
MedPage Today Youtube Channel: / medpagetoday
Medpage Today on Facebook: / medpagetoday